Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

Friday’s announcement comes after Moderna announced a sweeping headcount reduction earlier this week that will see it slash ...

Today, Benzinga 's options scanner spotted 17 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 52% bullish and 35%, bearish.

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

It also intends to present data from the P304 study at a future medical meeting. MRNA Stock Price Performance Post the above news, shares of Moderna rose nearly 2% yesterday.